IGHE and infection: Systemic safety was thoroughly evaluated, with no significant differences in systemic immune responses, allergic reactions, infections, or inflammatory markers, including TNF‐α, IgE, IgG, CRP, and IL‐1β, between Day 0 and Day 28.